|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mithraprabhu S, Kalff A, Chow A, Khong T
and Spencer A: Dysregulated Class I histone deacetylases are
indicators of poor prognosis in multiple myeloma. Epigenetics.
9:1511–1520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moreaux J, Reme T, Leonard W, Veyrune JL,
Requirand G, Goldschmidt H, Hose D and Klein B: Gene
expression-based prediction of myeloma cell sensitivity to histone
deacetylase inhibitors. Br J Cancer. 109:676–685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dimopoulos M, Siegel DS, Lonial S, Qi J,
Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt
H, et al: Vorinostat or placebo in combination with bortezomib in
patients with multiple myeloma (VANTAGE 088): A multicentre,
randomised, double-blind study. Lancet Oncol. 14:1129–1140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
San-Miguel JF, Hungria VT, Yoon SS, Beksac
M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn
TN, Siritanaratkul N, et al: Panobinostat plus bortezomib and
dexamethasone versus placebo plus bortezomib and dexamethasone in
patients with relapsed or relapsed and refractory multiple myeloma:
A multicentre, randomised, double-blind phase 3 trial. Lancet
Oncol. 15:1195–1206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raje NS, Bensinger W, Cole CE, Lonial S,
Jagannath S, Arce-Lara CE, Valent J Rosko AE, Harb WA, Sandhu PG,
et al: Ricolinostat (ACY-1215), the first selective HDAC6
inhibitor, combines safely with pomalidomide and dexamethasone and
shows promosing early results in relapsed- and- refractory myeloma
(ACE-MM-102 Study). Blood. 126:42282015.
|
|
9
|
Bradner JE, West N, Grachan ML, Greenberg
EF, Haggarty SJ, Warnow T and Mazitschek R: Chemical phylogenetics
of histone deacetylases. Nat Chem Biol. 6:238–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pan DS, Yang QJ, Fu X, Shan S, Zhu JZ,
Zhang K, Li ZB, Ning Q and Lu XP: Discovery of an orally active
subtype-selective HDAC inhibitor, chidamide, as an epigenetic
modulator for cancer treatment. Med Chem Commun. 5:1789–1796. 2014.
View Article : Google Scholar
|
|
11
|
Ning ZQ, Li ZB, Newman MJ, Shan S, Wang
XH, Pan DS, Zhang J, Dong M, Du X and Lu XP: Chidamide
(CS055/HBI-8000): A new histone deacetylase inhibitor of the
benzamide class with antitumor activity and the ability to enhance
immune cell-mediated tumor cell cytotoxicity. Cancer Chemoth Pharm.
69:901–909. 2012. View Article : Google Scholar
|
|
12
|
Liu Z, Ding K, Li L, Liu H, Wang Y, Liu C
and Fu R: A novel histone deacetylase inhibitor Chidamide induces
G0/G1 arrest and apoptosis in myelodysplastic syndromes. Biomed
Pharmacother. 83:1032–1037. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong K, Xie J, Yi H and Li W: CS055
(Chidamide/HBI-8000), a novel histone deacetylase inhibitor,
induces G1 arrest, ROS-dependent apoptosis and differentiation in
human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Yan X, Guo W, Huang X, Huang J, Yu
M, Ma Z, Xu Y, Huang S, Li C, et al: Chidamide in FLT3-ITD positive
acute myeloid leukemia and the synergistic effect in combination
with cytarabine. Biomed Pharmacother. 90:699–704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi P, Zhang L, Chen K, Jiang Z, Deng M,
Zha J, Guo X, Li P and Xu B: Low-dose decitabine enhances
chidamide-induced apoptosis in adult acute lymphoblast leukemia,
especially for p16-deleted patients through DNA damage.
Pharmacogenomics. 18:1259–1270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Zhang C, Sui X, Cao S, Tang F, Sun
S, Wang S and Chen B: Histone deacetylase inhibitor chidamide
induces growth inhibition and apoptosis in NK/T lymphoma cells
through ATM-Chk2-p53-p21 signalling pathway. Invest New Drugs.
36:571–580. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K,
Yue XP, Nie LP, Wan J, Lu XP, Zhang W and Ning ZQ: Non-toxic dose
chidamide synergistically enhances platinum-induced DNA damage
responses and apoptosis in non-small-cell lung cancer cells. Biomed
Pharmacother. 68:483–491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Guo Y, Fu M, Liang X, Zhang X,
Wang R, Lin C and Qian H: Antitumor activity of Chidamide in
hepatocellular carcinoma cell lines. Mol Med Rep. 5:1503–1508.
2012.PubMed/NCBI
|
|
19
|
Liu L, Chen B, Qin S, Li S, He X, Qiu S,
Zhao W and Zhao H: A novel histone deacetylase inhibitor Chidamide
induces apoptosis of human colon cancer cells. Biochem Biophys Res
Commun. 392:190–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He M, Qiao Z, Wang Y, Kuai Q, Li C, Wang
Y, Jiang X, Wang X, Li W, He M, et al: Chidamide inhibits aerobic
metabolism to induce pancreatic cancer cell growth arrest by
promoting Mcl-1 degradation. PLoS One. 11:e01668962016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu R, Liu T, Zhu X, Gan H, Wu Z, Li J,
Zheng Y, Dou G and Meng Z: Development and validation of a
sensitive HPLC-MS/MS method for determination of chidamide
(epidaza), a new benzamide class of selective histone deacetylase
inhibitor, in human plasma and its clinical application. J
Chromatogr B Analyt Technol Biomed Life Sci. 1000:181–186. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P,
Zhao W, Zhang H, Sun X, Yang H, et al: Chidamide in relapsed or
refractory peripheral T cell lymphoma: A multicenter real-world
study in China. J Hematol Oncol. 10:692017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bose P, Dai Y and Grant S: Histone
deacetylase inhibitor (HDACI) mechanisms of action: Emerging
insights. Pharmacol Ther. 143:323–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao B and He T: Chidamide, a histone
deacetylase inhibitor, functions as a tumor inhibitor by modulating
the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. Oncol Rep.
33:304–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Chen K, Zhou Y, Xiao Y, Deng M,
Jiang Z, Ye W, Wang X, Wei X, Li J, et al: A new strategy to target
acute myeloid leukemia stem and progenitor cells using chidamide, a
histone deacetylase inhibitor. Curr Cancer Drug Targets.
15:493–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao S, Guo J, Zhao Y, Fei C, Zheng Q, Li
X and Chang C: Chidamide, a novel histone deacetylase inhibitor,
inhibits the viability of MDS and AML cells by suppressing
JAK2/STAT3 signaling. Am J Transl Res. 8:3169–3178. 2016.PubMed/NCBI
|
|
28
|
Lin SH, Wang BY, Lin CH, Chien PJ, Wu YF,
Ko JL and Chen JJ: Chidamide alleviates TGF-β-induced
epithelial-mesenchymal transition in lung cancer cell lines. Mol
Biol Rep. 43:687–695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang T, Wang F, Hu L, Cheng X, Zheng Y,
Liu T and Jia Y: Chidamide and decitabine can synergistically
induce apoptosis of Hodgkin lymphoma cells by up-regulating the
expression of PU.1 and KLF4. Oncotarget. 8:77586–77594. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lundberg AS and Weinberg RA: Functional
inactivation of the retinoblastoma protein requires sequential
modification by at least two distinct cyclin-cdk complexes. Mol
Cell Biol. 18:753–761. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: Cyclin D1: Normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Imoto M, Doki Y, Jiang W, Han EK and
Weinstein IB: Effects of cyclin D1 overexpression on G1
progression-related events. Exp Cell Res. 236:173–180. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karimian A, Ahmadi Y and Yousefi B:
Multiple functions of p21 in cell cycle, apoptosis and
transcriptional regulation after DNA damage. DNA Repair (Amst).
42:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hirao A, Kong YY, Matsuoka S, Wakeham A,
Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA damage-
induced activation of p53 by the checkpoint kinase Chk2. Science.
287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bretones G, Delgado MD and León J: Myc and
cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Golay J, Cuppini L, Leoni F, Micò C,
Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, et
al: The histone deacetylase inhibitor ITF2357 has anti-leukemic
activity in vitro and in vivo and inhibits IL-6 and VEGF production
by stromal cells. Leukemia. 21:1892–1900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kaiser M, Zavrski I, Sterz J, Jakob C,
Fleissner C, Kloetzel PM, Sezer O and Heider U: The effects of the
histone deacetylase inhibitor valproic acid on cell cycle, growth
suppression and apoptosis in multiple myeloma. Haematologica.
91:248–251. 2006.PubMed/NCBI
|
|
39
|
Maiso P, Carvajal-Vergara X, Ocio EM,
López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A and San
Miguel JF: The histone deacetylase inhibitor LBH589 is a potent
antimyeloma agent that overcomes drug resistance. Cancer Res.
66:5781–5789. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Catley L, Weisberg E, Tai YT, Atadja P,
Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R,
Chauhan D, et al: NVP-LAQ824 is a potent novel histone deacetylase
inhibitor with significant activity against multiple myeloma.
Blood. 102:2615–2622. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lavelle D, Chen YH, Hankewych M and
DeSimone J: Histone deacetylase inhibitors increase p21(WAF1) and
induce apoptosis of human myeloma cell lines independent of
decreased IL-6 receptor expression. Am J Hematol. 68:170–178. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitsiades N, Mitsiades CS, Richardson PG,
McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D,
Munshi NC, Hideshima T, et al: Molecular sequelae of histone
deacetylase inhibition in human malignant B cells. Blood.
101:4055–4062. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu L, Qiu S, Liu Y, Liu Z, Zheng Y, Su X,
Chen B and Chen H: Chidamide and 5-flurouracil show a synergistic
antitumor effect on human colon cancer xenografts in nude mice.
Neoplasma. 63:193–200. 2016.PubMed/NCBI
|
|
44
|
Mazars GR, Portier M, Zhang XG, Jourdan M,
Bataille R, Theillet C and Klein B: Mutations of the p53 gene in
human myeloma cell lines. Oncogene. 7:1015–1018. 1992.PubMed/NCBI
|
|
45
|
Miller CP, Singh MM, Rivera-Del Valle N,
Manton CA and Chandra J: Therapeutic strategies to enhance the
anticancer efficacy of histone deacetylase inhibitors. J Biomed
Biotechnol. 2011:5142612011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Feng R, Ma H, Hassig CA, Payne JE, Smith
ND, Mapara MY, Hager JH and Lentzsch S: KD5170, a novel
mercaptoketone-based histone deacetylase inhibitor, exerts
antimyeloma effects by DNA damage and mitochondrial signaling. Mol
Cancer Ther. 7:1494–1505. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Khan SB, Maududi T, Barton K, Ayers J and
Alkan S: Analysis of histone deacetylase inhibitor, depsipeptide
(FR901228), effect on multiple myeloma. Br J Haematol. 125:156–161.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Schwartz C, Palissot V, Aouali N, Wack S,
Brons NH, Leners B, Bosseler M and Berchem G: Valproic acid induces
non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Int J Oncol. 30:573–582. 2007.PubMed/NCBI
|
|
49
|
Li Y, Chen K, Zhou Y, Xiao Y, Deng M,
Jiang Z, Ye W, Wang X, Wei X, Li J, et al: A new strategy to target
acute myeloid leukemia stem and progenitor cells using chidamide, a
histone deacetylase inhibitor. Curr Cancer Drug Targets.
15:493–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
